The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy
Abstract
Abstract. Backround: The prognostic and predictive value of KRAS mutation in non-small cell lung cancer (NSCLC) is not well established.
The present study is aimed at an elucidation of a role of KRAS mutation in prediction of outcome of patients with advanced NSCLC receiving second or third line chemotherapy. Patients and Methods: The outcome of 127 patients with advanced NSCLC who recieved pemetrexed or docetaxel at 2nd or 3rd line therapy was retrospectively analyzed.
Results: Progression-free survival (PFS) was not significantly different between KRAS mutated and KRAS wild-type patients. The results were the same even if we have taken into account the specific types of KRAS mutations.
Overall survival (OS) was significatnly longer for KRAS wild-type vs. KRAS mutated patients (16.1 vs.7.2 months).
We observed shorter OS for G12C KRAS mutation vs. other KRAS mutation group of patients (median OS 10.3 vs 6.4 months). Conclusion: We observed that presence of KRAS mutation (especially KRAS G12C mutation) correlated with adverse prognosis in patients treated with 2nd or 3rd line pemetrexed or docetaxel.